Morphic Holding Inc
NASDAQ:MORF

Watchlist Manager
Morphic Holding Inc Logo
Morphic Holding Inc
NASDAQ:MORF
Watchlist
Price: 56.99 USD Market Closed
Market Cap: 2.9B USD

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
Morphic Holding Inc
NASDAQ:MORF
2.9B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
382B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
160.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.2B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.6B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.2B USD
Loading...
No Stocks Found

Market Distribution

Not Available
No Country distribution data available for this multiple

Morphic Holding Inc
Glance View

Market Cap
2.9B USD
Industry
Biotechnology

Morphic Holding Inc. is a biotech firm paving new roads in the world of medicine by focusing on integrins, a class of proteins that are critical in various cellular processes but have long eluded effective therapeutic targeting. Born from the fertile intellectual fields of Harvard, Morphic was fueled by decades of research in integrin science, spearheaded by scientific luminaries like Professor Timothy A. Springer. The company's mission is to create oral integrin therapies—drugs that manipulate these proteins to treat conditions such as fibrosis, autoimmune diseases, and cancer. The unique approach involves leveraging structural biology and advanced chemistry to develop small molecule inhibitors, which are orally available, as opposed to the biologics traditionally used in targeting integrins. This innovation is an answer to the persistent demand for more patient-friendly treatments, which could potentially revolutionize the way certain chronic conditions are managed. Morphic makes its financial strides through strategic partnerships and collaborations with major pharmaceutical companies that see promise in their cutting-edge technology. These alliances support Morphic not only with direct funding but also through developmental milestones and subsequent royalties from the commercial success of any approved therapies. A key partnership with AbbVie, for example, underscores the potential seen in Morphic's pipeline, particularly in addressing immuno-inflammatory diseases. Furthermore, by continually advancing its proprietary MORF-057 and other candidates through clinical trials and regulatory pathways, Morphic aims to bring their innovative solutions to market. It's this blend of visionary science with pragmatic business acumen, underlined by robust intellectual property and productive alliances, that shapes Morphic's strategy in carving out a niche in the competitive biotech landscape.

MORF Intrinsic Value
0.06 USD
Overvaluation 100%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top